



Cell-Free DNA BCT®

Cell-Free DNA BCT is a direct-draw venous whole blood collection device intended for the collection, stabilization, and transport of venous whole blood samples for use in conjunction with cell-free DNA next-generation sequencing liquid biopsy assays that have been cleared or approved for use with samples collected in the Cell-Free DNA BCT device.

Making history

Over 10 years ago, Streck introduced Cell-Free DNA as the first blood collection tube designed to help researchers with pre-analytical variation in plasma cell-free DNA based studies. Now, after being granted De Novo status recognizing it as a novel medical device, it is the first and only FDA cleared whole blood collection tube that stabilizes cell-free DNA and reduces the release of cellular genomic DNA. The tube limits the compromising stresses of sample handling, shipping and storage which can lead to the lysis of nucleated blood cells and compromised sample integrity. Validated for the Guardant360® CDx assay, a next-generation sequencing liquid biopsy, critical whole blood samples from cancer patients are maintained for up to 7 days prior to extraction and analysis.

Features

- + First and only cell-free DNA stabilizing whole blood collection device cleared by U.S. FDA
- + Reduces the release of cellular genomic DNA when compared to K₂EDTA
- + Cleared for approved next-generation sequencing assays for liquid biopsy*

*Performance characteristics of this device have only been established for the Guardant360 CDx assay

Ordering information

IVD	
Description	Catalog#
6-tube pack	230469
100-tube box	230470
1000-tube case	230471